Boehringer taps CLS

MINNEAPOLIS: Boehringer Ingelheim Vetmedica, a subsidiary of Boehringer Ingelheim Corp., has chosen Carmichael Lynch Spong as its AOR. The firm has begun work already on the launch of Vetmedin Chewable Tablets, the first canine drug approved by the FDA in a decade.

MINNEAPOLIS: Boehringer Ingelheim Vetmedica, a subsidiary of Boehringer Ingelheim Corp., has chosen Carmichael Lynch Spong as its AOR. The firm has begun work already on the launch of Vetmedin Chewable Tablets, the first canine drug approved by the FDA in a decade.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in